Literature DB >> 31632757

Update on management of stable chronic obstructive pulmonary disease.

Ritwick Agrawal1,2, Shahram Moghtader1,2, Uma Ayyala1,2, Venkata Bandi1,2, Amir Sharafkhaneh1,2.   

Abstract

Chronic obstructive pulmonary disease (COPD) is a major chronic debilitating condition with significant impact on quality of life, symptoms, comorbidity, health care utilization and longevity. The main pathophysiological hallmark of COPD is expiratory flow limitation which impairs the ability of respiratory system to adequately and properly ventilate. To be able to prognosticate and manage patients with COPD, various societies have developed classifications of disease severity. Current classification schemes combine three elements that include lung function, patient reported symptoms (shortness of breath) and frequency of exacerbations. Global Initiative for Obstructive Lung Disease (GOLD), an international guideline for diagnosis and management of COPD, started using this approach since the 2011 revision. Management according to this scheme has been developed and is in use. Comprehensive COPD management is multifaceted. It includes pharmacologic management, patient education, smoking cessation, influenza and pneumococcal vaccinations, depression and anxiety management, pulmonary rehabilitation, and if indicated, home oxygen therapy. The following chapter will review management recommendations currently in use for stable COPD. We intend to make the chapter to the point and practical and avoid an exhaustive review of the literature. 2019 Journal of Thoracic Disease. All rights reserved.

Entities:  

Keywords:  Pharmacotherapy; bronchodilator; disease management

Year:  2019        PMID: 31632757      PMCID: PMC6783725          DOI: 10.21037/jtd.2019.06.12

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  62 in total

1.  E-cigarettes: the need for clear communication on relative risks.

Authors:  Ann McNeill; Leonie S Brose; Robert Calder; Sara C Hitchman; Peter Hajek; Hayden McRobbie
Journal:  Lancet       Date:  2015-08-31       Impact factor: 79.321

2.  Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial.

Authors:  D Tashkin; R Kanner; W Bailey; S Buist; P Anderson; M Nides; D Gonzales; G Dozier; M K Patel; B Jamerson
Journal:  Lancet       Date:  2001-05-19       Impact factor: 79.321

3.  Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial.

Authors:  Donald P Tashkin; Stephen Rennard; J Taylor Hays; Wendy Ma; David Lawrence; Theodore C Lee
Journal:  Chest       Date:  2010-09-23       Impact factor: 9.410

Review 4.  Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.

Authors:  Jimmy Chong; Bonnie Leung; Phillippa Poole
Journal:  Cochrane Database Syst Rev       Date:  2017-09-19

5.  Clinical efficacy of anti-pneumococcal vaccination in patients with COPD.

Authors:  I Alfageme; R Vazquez; N Reyes; J Muñoz; A Fernández; M Hernandez; M Merino; J Perez; J Lima
Journal:  Thorax       Date:  2005-10-14       Impact factor: 9.139

6.  Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials.

Authors:  Fernando J Martinez; Klaus F Rabe; Peter M A Calverley; Leonardo M Fabbri; Sanjay Sethi; Emilio Pizzichini; Andrew McIvor; Antonio Anzueto; Vijay K T Alagappan; Shahid Siddiqui; Colin Reisner; Sofia Zetterstrand; Jonas Román; Debasree Purkayastha; Nitin Bagul; Stephen I Rennard
Journal:  Am J Respir Crit Care Med       Date:  2018-11-15       Impact factor: 21.405

7.  Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD.

Authors:  Luigino Calzetta; Mario Cazzola; Maria Gabriella Matera; Paola Rogliani
Journal:  Chest       Date:  2019-01-17       Impact factor: 9.410

Review 8.  LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.

Authors:  Gustavo J Rodrigo; David Price; Antonio Anzueto; Dave Singh; Pablo Altman; Giovanni Bader; Francesco Patalano; Robert Fogel; Konstantinos Kostikas
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-03-17

Review 9.  A systematic review of possible serious adverse health effects of nicotine replacement therapy.

Authors:  Peter N Lee; Marc W Fariss
Journal:  Arch Toxicol       Date:  2016-10-03       Impact factor: 5.153

10.  Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis.

Authors:  Yuji Oba; Siva T Sarva; Sofia Dias
Journal:  Thorax       Date:  2015-10-21       Impact factor: 9.139

View more
  6 in total

1.  Study on the Management of the Health Status of Patients with Stable Chronic Obstructive Pulmonary Disease Treated with Double Bronchodilator.

Authors:  Wei Wang; Qing Yang; Qiufen Xun; Xiaoqun Ye
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-09       Impact factor: 2.650

2.  An Add-On Treatment for Moderate COPD with Squill-Oxymel (a Traditional Formulation from Drimia maritima (L.) Stearn): A Pilot Randomized Triple-Blinded Placebo-Controlled Clinical Trial.

Authors:  Maryam Mohammadi-Araghi; Alireza Eslaminejad; Hossein Karegar-Borzi; Saeideh Mazloomzadeh; Fatemeh Nejatbakhsh
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-30       Impact factor: 2.650

3.  [Deterioration of gas exchange in subjects with an increase in body mass index at an altitude of 2,240 meters above sea level].

Authors:  Luis E Santos-Martínez; Leticia Gómez-López; Adrián Arias-Jiménez; Javier Quevedo-Paredes
Journal:  Arch Cardiol Mex       Date:  2021

4.  Effect of Tiotropium Soft Mist Inhalers on Dynamic Changes in Lung Mechanics of Patients with Chronic Obstructive Pulmonary Disease Receiving Mechanical Ventilation: A Prospective Pilot Study.

Authors:  Pin-Kuei Fu; Yu-Feng Wei; Chau-Chyun Sheu; Chen-Yu Wang; Chi-Kuei Hsu; Chia-Min Chen; Wei-Chih Chen; Kuang-Yao Yang
Journal:  Pharmaceutics       Date:  2020-12-31       Impact factor: 6.321

5.  Effect of respiratory rehabilitation training on elderly patients with COVID-19: A protocol for systematic review and meta-analysis.

Authors:  Huan Yan; Yonghong Ouyang; Lang Wang; Xiangjun Luo; Qian Zhan
Journal:  Medicine (Baltimore)       Date:  2020-09-11       Impact factor: 1.817

6.  A protocol of randomized controlled trial for Modified Xiaoyao Powder in the treatment of chronic obstructive pulmonary disease combined mild to moderate depression.

Authors:  Keling Chen; Keni Zhao; Wujun Wang; Wei Xiao; Jing Xiao; Yang Yang; Yufei Liu; Xiaohong Xie
Journal:  Medicine (Baltimore)       Date:  2020-11-20       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.